Pharmacokinetics of oral antifungal agents

Dermatologic Therapy

Volumn 3, Issue , 1997, Pages 46-57

  De Doncker, Piet ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002757554     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Janssen PAJ, Cauwenbergh G. Antifungal therapy of the future. In: Jacobs PH, Nall L, ed. Antifungal drug therapy. A complete guide for the practitioner. New York: Marcel Dekker, 1990: 315-328.
2. De Doncker P. Pharmacokinetics in onychomycosis. In: Jacobs PH, Nall L, ed. Fungal disease; biology, immunologics and diagnostics. New York: Marcel Dekker (in press).
3. Cauwenbergh G. Skin kinetics of azole antifungal drugs. In: Gorgers M, Hay R, Rinaldi MG, ed. Current topics in medical mycology. Vol. 4. New York: Springer-Verlag, 1992: 88-136.
4. Heykants J, Van Peer A, Lavrijsen K, Meuldermans W, Woestenborghs R, Canwenbergh G. Pharmacokinetics of oral antifungals and their clinical implications. Br J Clin Pract 1990: 44(suppl): 50-56.
5. Shah VP. Migration of drugs across the skin after oral administration: griseofulvin. Pharmacol Skin 1987: 1: 41-49.
6. 6CL, metabolic product of Penicillium griseofulvum dierckx. Biochemistry 1939: 33: 240-248.
7. Riehl G. Griseofulvin: peroral wirkendes antimykoticum. Hautarzt 1959: 10: 136.
8. Rowland M, Riegelman S, Epstein L. Absorption kinetics of griseofulvin in man. J Pharm Sci 1968: 57: 984-989.
9. Chiou LW, Riegelman S. Absorption characteristics of solid dispersed and micronized griseofulvin in man. J Pharm Sci 1971: 60: 1376-1380.
10. Sande MA, Mandell GL. Antifungal and antiviral agents. In: Goodman Gilman A, Goodman LS, Rall TW, Murad T, ed. The pharmacological basis of therapeutics. New York: Macmillan, 1985: 1224-1225.
11. Korting HC, Schafer-Korting M, Zienicke H, Georgii A, Ollert MW. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother 1993: 37: 2064-2068.
12. Artis WM. Final pathway for delivery of oral antifungals to keratinized cornified skin. In: Meinhof W, ed. Oral therapy in dennatomycosis: a step forward. Oxford: Medicine Publishing Foundation, Series 16, 1985: 61-70.
13. Epstein WL, Shah VP, Riegelman S. Griseofulvin levels in stratum corneum. Study after oral administration in man. Arch Dermatol 1972: 106: 344-348.
14. Shah VP, Epstein WL, Riegelman S. Role of sweat in accumulation of orally administered griseofulvin in skin. J Clin Invest 1974: 53: 1673-1678.
15. Oskui J. Intermittent use of griseofulvin in tinea capitis. Cutis 1978: 21: 81-83.
16. Dawber R, Van Neste D. In: Hair and scalp disorders. Common presenting signs, differential diagnosis and treatment. London: Martin Dunitz, 1995.
17. Heeres J, Backx LJJ, Mostmans JH, Van Cutsem J. Antimycotic imidazoles. 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent. J Med Chem 1979: 22: 1003-1005.
18. Cauwenbergh G. New and prospective developments in antifungal drugs. Acta Derm Venereol (Stockh) 1986: 121: 147-153.
19. Levine HB, ed. Ketoconazole in the management of fungal disease. Hong Kong: Adis Press, 1982.
20. Lewawongs P, Barone JA, Colalzzi JL et al. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm 1988: 7: 228-235.
21. Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants J. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother 1986: 30: 206-210.
22. Badcock NR, Bartholomeusz FD, Frewin DB, Sansom LN, Reid JG. The pharmacokinetics of ketoconazole after chronic administration in adults. Eur J Clin Pharmacol 1987: 33: 531-534.
23. Van Tyle JH. Ketoconazole: mechanism of action, spectrum of activity, pharmacodynamics, drug interactions, adverse reactions, and therapeutic use. Pharmacotherapy 1984: 4: 343-373.
24. Daneshmend TK, Warnock DW, Turner A et al. Pharmacokinetics of ketoconazole in normal subjects. J Antimicrob Chemother 1981: 8: 299-304.
25. Gupta A, Sauder DN, Shear N. Antifungal agents: an overview. Part I. J Am Acad Dermatol 1994: 30: 677-698.
26. Bergan T. Pharmacokinetics of the azole antifungal agents: distinguishing differences. Antiinfect Drugs Chemother 1995: 13: 149-159.
27. Lake-Bakaar GF, Quadros S, Beidas S et al. Gastric secretory failure in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988: 109: 402-404.
28. Lake-Bakaar GF, Tom W, Lake-Bakaar et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988: 109: 471-473.
29. Hann IM, Prentice HG, Corringham R et al. The pharmacokinetics of ketoconazole in severely immunocompromised patients. J Antimicrob Chemother 1982: 10: 489-496.
30. van den Auker JN, van Lingen RA, Koster M, Heykants J, Sauer PJJ. Insufficient ketoconazole concentrations in preterm infants with fungal infections. Eur J Pediatr 1993: 152: 538.
31. Brass C, Galgiani JN, Blaschke TF et al. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother 1982: 21: 151-158.
32. Gascoigne EW, Barton GJ, Michiels M, Meuldermans W, Heykants J. The kinetics of ketoconazole in animals and man. Clin Res Rev 1981: 1: 177-187.
33. Clissold SP. Pharmacokinetic properties. In: Jones HE, ed. Ketoconazole today. A review of clinical experience. Manchester: Adis Press Limited, 1987: 19-28.
34. Haneke E. Tissue concentrations of ketoconazole after treatment. In: Meinholf W, ed. Oral therapy in dermatomycosis: a step forward. Oxford: Medicine Publishing Foundation, series 16, 1985: 71-72.
35. Heel RC, Brogden RN, Carmine A et al. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 1982: 23: 1-36.
36. Cissold SP. Clinical experience in superficial fungal infections. In: Jones HE, ed. Ketoconazole today. A review of clinical experience. Manchester: Adis Press Limited, 1987: 19-28.
37. Van Cutsem J. An investigation of the in vitro activity and antifungal spectrum of itraconazole and terbinafine in relation to in vivo efficacy in dermatophytosis. J Mycol Med 1994: 4: 137-144.
38. Ryder N, Frank I. Interaction of terbinafine with human serum and serum proteins. J Med Vet Mycol 1992: 30: 451-460.
39. Jenssen J. Pharmacokinetics in humans. J Dermatol Treat 1990: 1(suppl 2): 15-18.
40. Kovarik J, Kirkesseli S, Humbert H et al. Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers. Br J Dermatol 1992: 126(suppl 2): 15-18.
41. Samsoen M. Terbinafine (Lamisil): the first oral fungi-static and fungicidal allylamine. Nouv Dermatol 1992: 11: 743-762.
42. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992: 43: 259-284.
43. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. II. J Am Acad Dermatol 1994: 30: 911-933.
44. Breckenridge A. Clinical significance of interactions with antifungal agents. Br J Dermatol 1992; 126: 19-22.
45. Lever L, Dykes P, Thomas R et al. How orally administered terbinafine reaches the stratum corneum. J Dermatol Treat 1990: 1(suppl 2): 23-26.
46. Faergemann J, Zehender H, Jones T et al. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol (Stockh) 1990: 71: 322-326.
47. Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair, and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994: 19: 121-126.
48. Piérard G, Arrese J, De Doncker P. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol 1995: 32: 429-435.
49. Finlay A, Lever L, Thomas R et al. Nail matrix kinetics of oral terbinafine in onychomycosis and normal nails. J Dermatol Treat 1990: 1(suppl 2): 51-54.
50. Finlay A. Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992: 126(suppl 39): 28-32.
51. Finlay A, Thomas R, Chawla M. Does the oral dosage of terbinafine influence its concentration in nail? Presented at Dermatology 2000 (symposium), May 18-21, 1991, Vienna, Austria. Abstract 40.
52. Effendy I, Mensing H, Schatz M et al. Preliminary results of nail kinetics of terbinafine. Presented at the International Summit on Cutaneous Antifungal Therapy, October 21, 1993, San Francisco, CA, USA. Abstract.
53. Dragos V, Podrumac B, Kralj B, Bartenjev I, Dolenc M. Terbinafine in tinea capitis due to Microsporum canis. Acta Derm Venereol (Stockh) Suppl 1995: 4: 195-197.
54. Brammer K, Tarbit M. A review of the pharmacokinetics of fluconazole (UK-49858) in laboratory animals and in man. In: Fromtling R, ed. Recent trends in the discovery, development and evaluation of antifungal agents. Barcelona: JR Prous Science Publishers, 1987: 12(suppl 3): 318-326.
55. Humphrey M, Jevons S, Tarbit M. Pharmacokinetic evaluation of UK-49858, a metabolically stable triazole antifungal drug in animals and humans. Antimicrob Agents Chemother 1985: 28: 648-653.
56. Grant S, Clissold S. Fluconazole: a review of it pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses. Drugs 1990: 39(6): 877-916.
57. Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother 1988: 32: 1-8.
58. Dudley MN. Clinical pharmacology of fluconazole. Pharmacotherapy 1990: 10(suppl): 141S-145S.
59. Debruyne D, Rychelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993: 24: 10-27.
60. Faergemann J, Laufen H. Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat. Clin Exp Dermatol 1993: 18: 102-106.
61. Hay R. Pharmacodynamic and pharmacokinetic evaluation of fluconazole in skin and nails. Int J Dermatol 1992: 31(suppl 2): 6-7.
62. Piérard GE, Rurangirwa A, Piérard-Francimont C. Bioavailability of fluconazole and ketoconazole in human stratum corneum and oral mucosa. Clin Exp Dermatol 1991: 16: 168-171.
63. Fraki J, Heikkila H, Kero M et al. Fluconazole in the treatment of onychomycosis: an open non-comparative study with oral 150 mg fluconazole once weekly. Presented at Dermatology 2000 (symposium); May 18-21, 1991, Vienna, Austria, Abstract 14.
64. Monterro-Gei F, Melendez M, Siles L et al. Fluconazole in the treatment of onychomycosis. Presented at the XI Congress of the International Society of Human and Animal Mycology, June 1991, Montreal, Canada, Abstract 3.84.
65. Kuokkanen K, Alava S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992: 3: 115-117.
66. Van Cutsem J, Van Gerven F, Janssen P. Activity of orally, topically and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis 1987: 9(suppl 1): 15-32.
67. Heykants J, Van Peer A, Van de Velde V et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989: 32(suppl): 67-87.
68. Bodey G. Azole antifungal agents. Clin Infect Dis 1992: 14(suppl 1): S161-S169.
69. Van Peer A, Woestenborghs R, Heykants J et al. The effect of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989: 36: 423-426.
70. Wishart JM. The influence of food on the pharmacokinetics or itraconazole in patients with superficial fungal infections. J Am Acad Dermatol 1987: 17: 220-223.
71. Hardin T, Graybill J, Fetchick R, Woestenborghs R, Rinaldi M, Kuhn J. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988: 32: 1310-1315.
72. Heykants J, Van Peer A, Lavrijsen K et al. Pharmacokinetics of oral antifungals and their clinical implications. Br J Clin Pract 1990: 44(suppl): 50-56.
73. Barone JA, Bierman RH, Colaizzi JL et al. Food interactions and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993: 37: 778-784.
74. De Doncker P, Decroix J, Piérard G et al. Antifungal pulse therapy in onychomycosis: a pharmacokinetic/pharmacodynamic investigation of monthly cycles of 1 week pulse with itraconazole. Arch Dermatol 1996: 132: 34-41.
75. Denning DW, Follansbee SE, Scolaro M et al. Pulmonary aspergillosis in the acquired immunodeficiency. N Engl J Med 1991: 324: 654-662.
76. Boogaerts MA, Verhoef GE, Zachee P et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989: 32(suppl): 103-108.
77. Yeates RA, Zimmermann T, Laufen H et al. Comparative pharmacokinetics of fluconazole and of itraconazole in Japanese and in German subjects. Int J Clin Pharmacol Ther 1995: 32: 131-135.
78. Yoovathaworn K, Stiwatanakul K, Van de Velde V et al. Pharmacokinetic studies on ethnic differences in itraconazole metabolism. Clinical research report on itraconazole, Janssen Research Foundation 1992 (N88685).
79. Cauwenbergh G, Degreef H, Heykants J et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988: 18(2): 263-268.
80. Matthieu L, De Doncker P, Cauwenbergh G et al. Itraconazole penetrates the nail via the nail matrix and the nail bed: an investigation in onychomycosis. Clin Exp Dermatol 1992: 16: 374-376.
81. Willemsen M, De Doncker P, Willems J et al. Post-treatment itraconazole levels in the nail. J Am Acad Dermatol 1992: 26(5): 731-735.
82. De Doncker P. Effects of itraconazole in relation to drug distribution and penetration in the nail. PhD thesis. Antwerp: Universiteit Antwerpen, 1995.
83. Baran R. Dawber RPR. Physical signs. In: Baran R, Dawber RPR, ed. Diseases of the nail and their management. 2nd edn. Boston: Blackwell Scientific Publications, 1994: 35-80.
84. Fleckman P. Basic science of the nail unit. In: Scher R, Daniel R, ed. Nails: therapy, diagnosis, surgery. Philadelphia: W.B. Saunders Company, 1990: 36-51.
85. De Doncker P. Rationale for pulse therapy for oral antifungal drugs. In: Odom R, ed. Proceedings of the 2nd International Symposium of Onychomycosis, September 28-29, 1995, Florence, Italy. Gardiner-Caldwell Communications 1996: 28-30.
86. Elewski B. Itraconazole pulse therapy for the treatment of fingernail onychomycosis. In: Odon R, ed. Proceedings of the 2nd International Symposium of Onychomycosis, September 28-29, 1995, Florence, Italy. Gardiner-Caldwell Communications 1996: 28-30.
87. Andre J. Itraconazole in onychomycosis: an update of recent data. In: Maddin S, Degreef H, ed. Proceedings of the 6th International Skin Symposium, April 24-26, 1996, Brussels, Belgium: 87.
88. Van Doorslaer E, Tormans G, Van Rossem K et al. Cost-effectiveness comparison of itraconazole continuous dosing, itraconazole pulse, terbinafine, and ciclopirox for the treatment of pedal onychomycosis. Presented at the American Academy of Dermatology 51st Annual Meeting, Washington, DC, February 1996.
89. Van Cutsem J. Therapeutic oral treatment with itraconazole solution of experimental microsporosis in cats. Efficacy and hair antifungal levels. Preclinical research report on itraconazole (R51211/85), December 1991, Janssen Research Foundation, Belgium.
90. Lopez-Gomez S, Del Palacio A, Van Cutsem J et al. Itraconazole versus griseofulvin in the treatment of tinea capitis: a double-blind study in children. Int J Dermatol 1994: 33(10): 743-744.